Targeted radionuclide therapy against GARP expressing T regulatory cells after tumour priming with external beam radiotherapy in a murine syngeneic model.
Fiche publication
Date publication
octobre 2024
Journal
Heliyon
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GARRIDO Carmen, Dr MIRJOLET Céline, Dr COLLIN Bertrand, Dr BELLAYE Pierre-Simon, Pr KOHLI Evelyne
Tous les auteurs :
Bellaye PS, Dias AM, Vrigneaud JM, Bouchard A, Moreau M, Petitot C, Bernhard C, Claron M, Froidurot L, Morgand V, Guillemin M, Monterrat M, Mirjolet C, Garrido C, Kohli E, Collin B
Lien Pubmed
Résumé
Radiation therapy (RT) exerts its anti-tumour efficacy by inducing direct damage to cancer cells but also through modification of the tumour microenvironment (TME) by inducing immunogenic antitumor response. Conversely, RT also promotes an immunosuppressive TME notably through the recruitment of regulatory T cells (Tregs). Glycoprotein A repetitions predominant (GARP), a transmembrane protein highly expressed by activated Tregs, plays a key role in the activation of TGF-β and thus promotes the immunosuppressive action of Tregs. The development of a theranostic approach targeting GARP combining imaging and targeted radionuclide therapy (TRT) was carried out.
Mots clés
External beam radiotherapy, GARP, SPECT imaging, T regulatory cells, Targeted radionuclide therapy
Référence
Heliyon. 2024 10 30;10(20):e39543